APA (7th ed.) Citation

Wermke, M., Nolte, F., & Hofmann, W. (2016). Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: Results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS). British journal of haematology, 175(5), . https://doi.org/10.1111/bjh.14345

Chicago Style (17th ed.) Citation

Wermke, Martin, Florian Nolte, and Wolf-Karsten Hofmann. "Mammalian-target of Rapamycin Inhibition with Temsirolimus in Myelodysplastic Syndromes (MDS) Patients Is Associated with Considerable Toxicity: Results of the Temsirolimus Pilot Trial by the German MDS Study Group (D-MDS)." British Journal of Haematology 175, no. 5 (2016). https://doi.org/10.1111/bjh.14345.

MLA (9th ed.) Citation

Wermke, Martin, et al. "Mammalian-target of Rapamycin Inhibition with Temsirolimus in Myelodysplastic Syndromes (MDS) Patients Is Associated with Considerable Toxicity: Results of the Temsirolimus Pilot Trial by the German MDS Study Group (D-MDS)." British Journal of Haematology, vol. 175, no. 5, 2016, https://doi.org/10.1111/bjh.14345.